Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

被引：24
|
作者：
Valle, JW
Dangoor, A
Beech, J
Sherlock, DJ
Lee, SM
Scarffe, JH
Swindell, R
Ranson, M
机构：
[1] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[2] N Manchester Grp Hosp, Pennine Acute Hosp NHS Trust, Manchester M8 5RB, Lancs, England
[3] Middlesex Hosp, London W1T 3AA, England
[4] Lister Hosp, E&N Herts NHS Trust, Stevenage SG1 4AB, Herts, England
来源：
BRITISH JOURNAL OF CANCER | 2005年 / 92卷 / 04期
关键词：
pegylated liposomal doxorubicin; hepatocellular carcinoma; phase II;
D O I：
10.1038/sj.bjc.6602394
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(-2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.
引用
收藏
页码：628 / 630
页数：3
相关论文
共 50 条
  • [41] Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer
    Lorusso, D
    Ferrandina, G
    Lo Voi, R
    Fagotti, A
    Scambia, G
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 98 - 103
  • [42] A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib and dexamethasone regime for patients with previously untreated multiple myeloma (MM)
    Berenson, J. R.
    Yellin, O.
    Chen, C.
    Patel, R.
    Bessudo, A.
    Boccia, R. V.
    Yang, H.
    Gupta, V.
    Hilger, J.
    Swift, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma
    Katsaros, D
    Oletti, MV
    de la Longrais, IAR
    Ferrero, A
    Celano, A
    Fracchioli, S
    Donadio, M
    Passera, R
    Cattel, L
    Bumma, C
    ANNALS OF ONCOLOGY, 2005, 16 (02) : 300 - 306
  • [44] Pegylated liposomal doxorubicin (PEG-LD) and paclitaxel in patients with metastatic breast carcinoma: A phase II study
    Leonardi, V
    Palmisano, V
    Pepe, A.
    Usset, A.
    Savio, G.
    Laudani, A.
    Calabria, C.
    Giresi, A.
    Carruba, G.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2006, 17 : XI10 - XI10
  • [45] Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure
    Mlineritsch, B
    Mayer, P
    Rass, C
    Reiter, E
    Russ, G
    Vesenmayer, G
    Oberaigner, W
    Hausmaninger, H
    ONKOLOGIE, 2004, 27 (05): : 441 - 446
  • [46] Pegylated liposomal doxorubicin (Peg-LD) and paclitaxel in patients with metastatic breast carcinoma: A phase II study
    Leonardi, Vita
    Palmisano, Valentina
    Pepe, Alessio
    Usset, Antonella
    Savio, Giuseppina
    Laudani, Agata
    Calabria, Caterina
    Rondello, Giacomo
    Carruba, Giuseppe
    Agostara, Biagio
    ANNALS OF ONCOLOGY, 2006, 17 : 85 - 85
  • [47] Pegylated liposomal doxorubicin (PEG-LD) and paclitaxel in patients with metastatic breast carcinoma: A phase II study
    Leonardi, V.
    Palmisano, V.
    Pepe, A.
    Savio, G.
    Laudani, A.
    De Bella, M. Tamburo
    Mesi, L.
    Agostana, B.
    ANNALS OF ONCOLOGY, 2005, 16 : 144 - 144
  • [48] Pegylated liposomal doxorubicin (PLD) as an alternative treatment of cutaneous T-cell lymphoma
    Quereux, G.
    Khammari, A.
    Nguyen, J. M.
    Benmiloud, M.
    Dreno, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] Phase II pilot study of Caelyx (doxorubicin HCl, pegylated liposomal) in patients with inoperable head and neck squamous cell cancer.
    Harrington, K
    Stewart, S
    Harrison, D
    Whittaker, J
    Elliott, P
    BRITISH JOURNAL OF CANCER, 1998, 78 : 34 - 34
  • [50] Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG)
    Janinis, J
    Stathopoulos, GP
    Nikolaidis, P
    Kalofonos, HP
    Kalogera-Fountzila, A
    Samantas, E
    Aravantinos, G
    Anagnostopoulos, A
    Tolis, C
    Makatsoris, T
    Rigatos, SK
    Bafaloukos, D
    Dimopoulos, MA
    Daniilidis, J
    Fountzilas, G
    ANTI-CANCER DRUGS, 2004, 15 (05) : 479 - 487
12345